Class of arylamide compounds useful as inhibitors of c-fms kinase

US7705042B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Carl R. Illig · Phoenixville, US
• Shelley K. Ballentine · Lansdale, US
• Jinsheng Chen · Exton, US
• Sanath K. Meegalla · Boothwyn, US
• Jonathan Rudolph · Doylestown, US
• Mark Wall · Lansdale, US
• Kenneth Wilson · Puntarenas, CR
• Renee Louise Desjarlais · Saint Davids, US
• Carl L. Manthey · Downingtown, US
• Christopher Flores · Lansdale, US
• Christopher Molloy · Yardley, US

Key dates

• Filing date: Oct 20, 2005
• Grant date: Apr 27, 2010
• Expiry date: Aug 22, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to arylamide and hetereoarylamide compounds of Formula I:wherein A, X, R2 and W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.